ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China
November 19, 2020Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. and Sagimet Biosciences Inc. jointly announced today that they have completed patient enrollment in the ASC40 (TVB-2640) Phase 2 NASH trial in China. -
Sagimet Announces Positive Results in NASH Trial of FASN Inhibitor TVB-2640
June 29, 2020Sagimet Biosciences announced positive results from FASCINATE-1, the Phase 2 clinical trial of its oral, once-daily FASN inhibitor TVB-2640, the company's lead product candidate that is currently being evaluated as a potential treatment for ...
Pharma Sources Insight January 2025
